Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30 2023 - 7:00AM
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting degenerative retinal diseases that have significant unmet
medical needs, today announced that it will be participating at the
Benchmark Company’s 12th Annual Discovery One-on-One Investor
Conference to be held Thursday, December 7, 2023, at the New York
Athletic Club in New York City.
To schedule a one-on-one meeting with management, you may submit
your request online via the link provided upon registration. To
register for the conference, please visit
https://www.meetmax.com/sched/event_99181/investor_reg_new.html?attendee_role_id=INVESTOR.
About Belite Bio Belite Bio is a
clinical-stage biopharmaceutical drug development company focused
on advancing novel therapeutics targeting degenerative retinal
diseases that have significant unmet medical needs, such as
Stargardt disease and geographic atrophy in advanced dry
age-related macular degeneration, in addition to specific metabolic
diseases. For more information, follow us
on Twitter, Instagram, LinkedIn, Facebook, or
visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wuir@belitebio.com
Julie Fallonbelite@argotpartners.com
Belite Bio (NASDAQ:BLTE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Belite Bio (NASDAQ:BLTE)
Historical Stock Chart
From Sep 2023 to Sep 2024